Healthy Life Area

Issues concerning intellectual property in the pharmaceutical industry are particularly acute, since effective legal regulation and enforcement in the industry directly affects how Russia protects the life and health of the population and the country’s drug independence. The rapid development of domestic pharmaceuticals has made it crucial to improve legal mechanisms, balance the interests of foreign copyright holders and domestic manufacturers, and harmonize the approaches that domestic and foreign intellectual property institutions take to establishing and extending patent protection. What gaps currently exist in patent regulation? What kind of support is available for domestic full-cycle manufacturers in terms of intellectual property issues? Can unified approaches be developed to the use of the compulsory licensing mechanism? What patent strategies of manufacturers and initiatives of regulators are optimal as Russia phases out imports of foreign medical products?

Moderator
Alevtina Penkalskaya, Financial Observer, RBC Investments; Presenter, RBC-TV

Panellists
Petr Bely, Founder and Chairman of the Board of Directors, Promomed Group
Sergey Glagolev, Deputy Minister of Health of the Russian Federation
Artem Zdunov, Head of the Republic of Mordovia
Yury Zubov, Head, Federal Service for Intellectual Property (Rospatent)
Vyacheslav Shulenin, General Director, Moscow Center for Healthcare Innovations